Loading
StoneWise builds AI software that designs new drug molecules, sells it to drug companies, and has started testing its own first cancer drug in people.
Beijing StoneWise Technology Co., Ltd. (望石智慧), headquartered in Haidian, Beijing with a Shanghai office, develops MolVado, a multimodal AI model that generates 3D small molecules, together with computational chemistry tools, and offers them to drug developers; it also develops its own oral small-molecule candidates. Its company page states it has completed several financing rounds totalling more than USD 100 million. SWA1211 tablets are in a first-in-human phase 1 study in advanced solid tumours (NCT07363967). Its first registered cancer trial, NCT07363967, was posted on ClinicalTrials.gov in January 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/